ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SCLP Scancell Holdings Plc

10.25
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 10.25 239,636 08:00:00
Bid Price Offer Price High Price Low Price Open Price
10.00 10.50 10.25 10.25 10.25
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 5.27M -11.94M -0.0129 -7.95 95.1M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:14:32 O 96 10.38 GBX

Scancell (SCLP) Latest News (1)

Scancell (SCLP) Discussions and Chat

Scancell Forums and Chat

Date Time Title Posts
28/3/202414:24Scancell investors thread (litter free)303
27/3/202407:16Scancell - Pot of Gold or POS?7,604
17/1/202414:12Scancell for investors (inanaco free thread)235
09/12/202309:53Using immunology to fight cancer.57,587
01/12/202315:26Scancell - BS free thread2

Add a New Thread

Scancell (SCLP) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:14:3310.38969.96O
15:40:2910.001,000100.00O
14:38:1710.4450,0005,220.00O
14:02:0610.185,000509.00O
13:33:3810.1527,9322,835.10O

Scancell (SCLP) Top Chat Posts

Top Posts
Posted at 28/3/2024 08:20 by Scancell Daily Update
Scancell Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 10.25p.
Scancell currently has 927,819,977 shares in issue. The market capitalisation of Scancell is £95,101,548.
Scancell has a price to earnings ratio (PE ratio) of -7.95.
This morning SCLP shares opened at 10.25p
Posted at 26/3/2024 09:39 by bermudashorts
Sci102

I'm sorry but MarkingTime is correct, Scancell is only obligated to disseminate information if it would likely have an impact on the Company's share price. The link you've posted confirms that! They don't have to publish every single poster, paper, research report, presentation etc. etc.

Having said that, I'm sure at some stage those posters will appear on their website but keeping their site updated has never been one of Scancell's strengths.

Your ban on MT is harsh - perhaps reconsider?
Posted at 07/3/2024 23:24 by supernumerary
Bermuda

yes - you just can't get good placebos these days :¬(

When you say 'sadly' I'm not so sure - from a patient's point of view it's good to have the losers winnowed, and in a way, nothing much has changed - all small biotechs spend their lives clambering up the north face of the Eiger - ulti just has to adapt to a steeper slope. I'd guess they're still funded further ahead than sclp?

But what happens now is an interesting question. They talk about sub-group analysis, but that would take probably 6 months or so to produce reliable results; then say 12 months to design and obtain approval for a more focused trial; then another 18 months minimum to run the trial and process results. A minimum total of 3 years which is well beyond their cash horizon, long after they've had other significant results, and meanwhile competitors will have raised the bar even further. So unless something really dramatic emerges, I think it's the end of the road for them with melanoma.

Of the remaining trials, I'm not a fan of head and neck - too heterogeneous, too distorted by other side-effects of the cancer (but I accept that's a personal view) - and nsclc and ovarian are not only hard, but face that ever-rising bar, which leaves mesothelioma.

A very difficult cancer, but it's a decent size market and there's not a lot of competition, so maybe that's the best option? They do have some results from NIPU, which was another ipi+nivo trial, but again they missed the primary (also pfs), however the secondaries didn't look too bad and I think were regarded as encouraging so they do have a chance.

Glad to be watching not holding - another bullet missed....

3n - I'm sure you're right and BMS is happy to see these results (putting aside minor questions of morality of course!), although it won't (I don't think) change their commercial position at all.

I also agree that comparisons with historical data mean little - one of the reasons sclp has been untouchable for me for many years now. As ever the problem is that the signals are so small, which is why the trials need to be so large and go on so long. We've reached a stage where progress is almost invariably made in tiny steps - the great leaps forward have gone until such time as a completely new model of cancer is achieved.

Your comments on pfs are interesting, thank you. It's really just a poignant illustration of the previous point - ipo and nivo have achieved a certain plateau, and climbing over that is necessarily a long and arduous process. It's also a reminder that sclp is far from out of the woods yet.

Anyway, assuming you're still holding, I wish you luck.
Posted at 03/2/2024 19:33 by chilltime
On the point of a low share price versus our perception of where we think it should be, Lindy perks up my interest there.

Various public companies can irrationally go ballistic on their share price based on hype, being the in thing catching market attention.

In the Pharma world it's been the immunotherapy PD1 scene. Antibodies that unmask cancer cells to allow our immune systems to go on the attack and destroy them.

Scancell are in the world of the a super boost for the attack with Scib.

So it seems nailed on, with positive results that vaccines will become a very hot topic to combine with other treatments. Given the it's all about money, those with a patent cliff would seek any means to extend patents and dominate the market.

Hence Lindy points to another company in the sector which she hopes has good results (due in a couple of months) as those results would put companies like Scancell in the spotlight.
Posted at 31/1/2024 18:11 by markingtime
33p per share, based on "overly conservative" assumptions?Its a damned good job we have some large, well-informed, shareholders because (if Lindy's comments are anywhere near accurate) there must be a high chance of attracting a bidder against a background of a share price that is simply wrong. I'll be surprised if the share price is below 33p by year end (a market cap of about £340mn)
Posted at 31/12/2023 08:02 by chillpill
HNY all. SCLP have 3 new institutions onboard. If we get more successful data released in the coming months the share price will start to re-rate sharply as the word spreads.
Posted at 07/12/2023 13:37 by inanaco
mia .... add the adjuvant resected market as well ............

scancells product will work just as well at this stage as later stage ... its the same cancer after all

miavoce

Posts: 610

Price: 11.75

No Opinion

ISCIB1+ - What is it worth ?Today 13:16
In somewhere between 12 and 18 months Scancell are likely to have enough data to convince big pharma that iSCIB1+ is sufficiently effective to make it worth licensing. So, what will big pharma have to pay and what will Scancell be worth.

The market for iSCIB1+ in non resectable melanoma will be $4.5bn (3 x the SCIB1 market size), so let's say that big pharma estimate that can achieve annual sales of $2bn. How much would they have to pay Scancell to buy that future annual revenue stream - my guess would be $1bn up front plus $500m in milestones. They would also need to give a significant royalty to Scancell given the fact that the risk of failure will be low - my guess would be 15%.

So, in 2025 Scancell might receive $1bn with the expectation of a further $500m over the following 2-3 years. This would certain push the share price towards the £1 mark irrespective of whatever else may be happening with our other products. Obviously the share price isn't going to stay at 12p until the deal is done - the progressive build up of positive data will make a deal more and more likely and the share price will rise in anticipation (not withstanding what may also be happening - e.g. trial data, deals - with our other products).

The real kicker comes in later however when the royalty stream builds. 15% of $2bn is $300m of pure profit for Scancell each year. Based on a PE ratio of just 10 this would give Scancell a valuation of $3bn or around £2 per share and there may also be a decent dividend. And this is just for iSCIB1+ ! As trials progress and deals are done for other products they will only add to the valuation.
Posted at 01/12/2023 10:05 by ih_486726
But the existing major investors already agreed to participate. A higher placing offer would change nothing for then except the company would issue fewer shares. As for the £2M to be raised from existing and new smaller shareholders, why would you prefer to be more diluted (most of the shares went to the big guys) and buy at 11p with the share price currently at that level, than buying at 14p also with the share price at that level. Plus the positivity a placing slightly above the current share price wouod create.

Again there might be good reason for this, I just don't get it :/
Posted at 28/11/2023 09:27 by chilltime
Chillpill

I take the lethargy on the share price of Scancell to be based on limited private investor awareness along with lack of promotion by the company or investor pumping.

Then combine that with an awful market where small cap companies have been decimated.

Ironically, if the Scancell share price was on a climb at double the current market cap then random investors would be more enthusiastic to buy shares.

On the current results path an inflexion point will appear and the upward trend will kick in, anything can trigger it, we have no idea how close deals are or even part or a full acquisition. It could double and treble in a flash.

Warren Buffett

Fearful when others are greedy, greedy when other fearful etc.

But with Scancell I'm not fearful, yes there can be risks but there are numerous eggs in the basket to cover much more than the current level, with current results worth in M/C terms far more than where it now sits.|

So the fearful definition for me equates quietly confident, and excited about the future.
Posted at 16/11/2023 10:52 by ruckrover
golcheja,My initial thoughts were in agreement with you but generally individuals having more control over their finances has got to be positive.However, that gives people the opportunity to invest wisely or otherwise. Has SCLP been a wise investment over the years?Well if you had invested your entire ISA allowance in SCLP on or around April 6th for the last 12 years you would currently be sitting on a GBP 9.5K profit. It is quite fortuitous that the share price was high (36p) when the allowance was low and low (5p) when the allowance was 20K in 2019/20.This represents an annual return of 5% about what you get in an instant access savings account today
Posted at 18/10/2023 12:15 by panama7
The Pfizer share price is dropping like a stone. The Governments and regulators around the world won’t admit it, but the market knows that Pfizer will face legal claims for damages due to the vaccine harms. Remind me again who was it that told you this 2 years ago. Pfizer share price down 36% YTD. Is this good news for Scancell's different approach or is it bad news for the Jab industry.
Scancell share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock